NCT05206305Active, not recruiting
Sensory-Evoked Cortical Gamma Oscillation
Sensory-Evoked Cortical Gamma Oscillation: Impact on Visual Processing and Cognitive Function in Patients With Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
The purpose of the study is to investigate the efficacy of cortical gamma oscillation on visual sensory processing and cognitive function in Alzheimer's Disease (AD) patients by combining a therapeutic sensory stimulation device capable of evoking 40-Hz gamma oscillation via non-invasive visual and auditory stimulation with pre-established markers of cortical network activity, i.e., electroencephalography (EEG) and event-related potentials (ERP), to evaluate the applicability of the 40-Hz multimodel sensory stimulation as a novel therapeutic approach for treatment of AD patients.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 17 Dec 2021
- Start date
- 1 Jul 2022
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- University of Tennessee Medical Center
- Diseases
- Alzheimer disease
- NCT number
- NCT05206305
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 1 Jul 2022 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Claustrophobic to the point that medication is required
Other illness
- Severe dementia
- Other medical conditions/neurodegenerative disease that could significantly impair cognitive abilities
- Cardiac pacemakers or any other implants that may not be compatible with MRI
Other
- Not fluent and literate in English
- Cognitively impaired to the point the patient is unable to consent for themselves
Who the study is looking for
- Individuals ages 60 and older with established diagnosis of Alzheimer's Disease as defined by the current consensus criteria for AD (Albert et al, 2011, Jack et al, 2011; McKhann et al, 2011)
- Fluent and literate in English language
- Able to consent for themselves based upon the MacArthur Competence Assessment Tool for Clinical Research
- Patients with a pre-existing positive A(beta)-PET and/or CSF tau/A(beta) markers or willingness to undergo a Lumbar Puncture (LP) with these results
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Tennessee Medical Center Coordinator of this site? Confirm its status | Knoxville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.